Interestingly, chronic administration of the glucagon/GLP-1 agonist in diet-induced obese (DIO) mice was able to reverse obesity, to improve hepatic steatosis and glucose tolerance, to increase metabolic rate, to decrease body fat mass, to reduce feeding, and to increase energy expenditure [35]. Here, GCG is linked to obesity disorder.